Generated by AI
Journey Medical Corp. Common Stock represents the equity of Journey Medical Corporation, a commercial-stage pharmaceutical company focused on developing, marketing, and selling prescription products for dermatological conditions in the United States. The company’s portfolio includes branded and authorized generic treatments used in areas such as acne, hyperhidrosis, fungal infections, and other skin disorders. Its current product lineup includes therapies such as Qbrexza, Accutane, Amzeeq, Targadox, Ximino, Zilxi, Exelderm, and Luxamend, reflecting a business centered on specialty dermatology care. Journey Medical Corp. serves a focused market within the broader pharmaceutical sector by commercializing FDA-approved products designed for physician-prescribed use. The stock is associated with a small-cap healthcare company whose role in the market is tied to the distribution and commercialization of dermatology medicines rather than broad consumer health products.
Website9237 East Via de Ventura Blvd.
Scottsdale, AZ, 85258
United States
The latest articles about DERM.
Journey Medical Corp (DERM) posted 8% revenue growth to $19 million and adjusted EBITDA of $3.5 million, fueled by Emrosi demand and a major national formulary win set for 2027.
Summary of Nov 17's posts. Generated by AI.
No summary yet.
Summary of Nov 4's posts. Generated by AI.
Summary of Jun 13's posts. Generated by AI.
Investors talking about DERM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.